Jump to content

MPM (drug)

From Wikipedia, the free encyclopedia
MPM
Clinical data
Other names4-Propoxy-2,5-dimethoxyamphetamine; 2,5-Dimethoxy-4-propoxyamphetamine
Drug classSerotonin 5-HT2 receptor agonist
ATC code
  • None
Identifiers
  • 1-(2,5-dimethoxy-4-propoxyphenyl)propan-2-amine
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC14H23NO3
Molar mass253.342 g·mol−1
3D model (JSmol)
  • COc1cc(OC)c(cc1OCCC)CC(C)N
  • InChI=1S/C14H23NO3/c1-5-6-18-14-8-11(7-10(2)15)12(16-3)9-13(14)17-4/h8-10H,5-7,15H2,1-4H3 checkY
  • Key:FTJOFRCENIVFLC-UHFFFAOYSA-N checkY
  (verify)

MPM, also known as 2,5-dimethoxy-4-propoxyamphetamine, is a lesser-known putative psychedelic drug of the phenethylamine, amphetamine, and DOx families.[1][2] It is a derivative of the DOx psychedelics TMA-2 and MEM in which the 4-position substituent has been extended.[1] The drug is also the α-methyl or amphetamine analogue of 2C-O-7.[1]

Use and effects

[edit]

In his book PiHKAL (Phenethylamines I Have Known and Loved), Alexander Shulgin gives the dose range as "30 mg or more" and the duration as "probably short".[1] The drug produced weak or threshold effects at doses of 15 to 30 mg.[1][3] In another publication, Shulgin estimated an effective dose of MPM to be around 50 mg and the drug as being around half as potent as TMA-2 or MEM.[4]

Pharmacology

[edit]

MPM produces the head-twitch response, a behavioral proxy of psychedelic effects, in rodents.[5] It shows about the same potency as TMA-2 and MEM in this test.[5]

History

[edit]

MPM was first described in the scientific literature by Shulgin in 1978.[3] Subsequently, Shulgin described the drug in more detail in his book PiHKAL.[1] The compound's name is said to derive from its benzene ring substituents, "methoxy propoxy methoxy".[2]

See also

[edit]

References

[edit]
  1. ^ a b c d e f MPM entry in PiHKAL on Erowid
  2. ^ a b Kolaczynska KE, Luethi D, Trachsel D, Hoener MC, Liechti ME (2019). "Receptor Interaction Profiles of 4-Alkoxy-Substituted 2,5-Dimethoxyphenethylamines and Related Amphetamines". Frontiers in Pharmacology. 10: 1423. doi:10.3389/fphar.2019.01423. PMC 6893898. PMID 31849671.
  3. ^ a b Shulgin AT (1978). "Psychotomimetic Drugs: Structure-Activity Relationships". In Iversen LL, Iversen SD, Snyder SH (eds.). Stimulants. Boston, MA: Springer US. pp. 243–333. doi:10.1007/978-1-4757-0510-2_6. ISBN 978-1-4757-0512-6.
  4. ^ Braun U, Braun G, Jacob P, Nichols DE, Shulgin AT (1978). "Mescaline Analogs: Substitutions at the 4-Position" (PDF). In Barnett G, Trsic M, Willette RE (eds.). QuaSAR: Quantitative Structure Activity Relationships Of Analgesics, Narcotic Antagonists, And Hallucinogens (PDF). National Institute on Drug Abuse Research Monograph Series. Vol. 22. National Institute on Drug Abuse. pp. 27–37. PMID 101882.
  5. ^ a b Halberstadt AL, Chatha M, Chapman SJ, Brandt SD (March 2019). "Comparison of the behavioral effects of mescaline analogs using the head twitch response in mice". J Psychopharmacol. 33 (3): 406–414. doi:10.1177/0269881119826610. PMC 6848748. PMID 30789291.
[edit]


Retrieved from "https://en.wikipedia.org/w/index.php?title=MPM_(drug)&oldid=1300555549"